About us

A fascinating story

We’re on a mission!

At MY01, we envision a world where every disease is quantifiable and every patient receives precise, personalized care.

We develop innovative tools that measure previously unquantified diseases, connecting care teams to better patient outcomes. We deliver significant value to patients, providers, and payers through proactive monitoring and actionable insights. Our tools set the standard in compartment syndrome, and this is just the beginning.

Growing since




Nationalities in Our Team




Physician-Patient engagement is key to effective healthcare.

Healthcare is human.

Our founders

team headshots grey background

Edward Harvey, MDCM

Chief Medical Officer

team headshots grey background

Charles Allan, M.Eng

Chief Executive Officer

team headshots grey background

George Xereas, PhD

Chief Technology Officer





Dr. Edward J. Harvey has a rich history of collaboration with basic, clinical and engineering scientists. He is a tenured Professor of Surgery at McGill University.  He is the trauma research program leader at the Research Institute of the McGill University Health Centre (RI-MUHC) with over 60 investigators in his group. He is, or has been, editor-in-chief of the Canadian Journal of Surgery; editorial board member of the Journal of Orthopaedic Trauma and OTA International; chairman of the Research Committee and the Annual meeting program chair for the Orthopedic Trauma Association; chair of the Trauma Section at the Orthopaedic Research Society; and president of the Canadian Orthopaedic Association amongst other national and international positions.





Charles is passionate about using really small things to solve big problems. Being surrounded by many successful and supportive entrepreneurs, he quickly gained an ability to create teams and transform problems into solutions.

An example of his passion at work can be found during his undergraduate years at Queens University, where he helped build a microfluidic pump for an implantable therapeutic for glaucoma. This project helped ignite his entrepreneurial spirit, and, while pursuing his Masters in Bioelectrical Engineering at McGill University, he formed a team that combined engineering and technology to develop microsolutions. Some of those initial microsystems are the foundational components used by the three companies that Charles founded: MY01, Inc., Stathera, Inc., and  NXTSENS Microsystems, Inc. These companies each have won several awards and been selected for important growth accelerators. They have grown to over 70 employees, and combined to raise over $50M in funding.





George  Xereas is the Chief Technology Officer at MY01 Inc. In this role, he leads the company’s technology and product development. Prior to MY01 Inc., he served as the Chief Technology Officer for NXTSENS Microsystems Inc., a fabless MEMS based sensor company he co-founded. George obtained his PhD in Electrical and Electronics Engineering from McGill University in 2017, which was supported by the Les Vadasz Doctoral Fellowship in Engineering – Intel.  George is an author in 19 high impact publications in MEMS sensors, and is an inventor in 14 utility patents.


March 2019

Company Incorporation

What started off as a Master’s project at McGill University, in March 2015, became an official startup as our founders: Charles, Ed, and George, officially registered the project as a corporate entity.

January 2020

CE Mark

MY01 receives positive notice from the European Commission to start selling our device across the European Union.

July 2020

FDA Clearance Granted

MY01 received its 510k clearance from the Food & Drug Administration (FDA) for its MY01 Continous Compartmental Pressure Monitor.

October 2021

Breakthrough Device Designation Granted

MY01 Inc. received its first-ever “Breakthrough Device” designation from the FDA, joining a select list of Orthopaedic companies to receive this designation since the program began in 2016.

December 2022

COTS Study

Completion of the clinical study surrounding the safety and functionality of MY01 in patients at risk for developing compartment syndrome. The trials were done in 6 sites across Canada from the largest level 1 trauma centers of the country.

April 2023

Quebec Study

The completion of the clinical study was used as a feasibility and safety trial to establish a baseline for pressures and what should be pressure triggers for surgical release (aka a fasciotomy).

April 2023

MY01 receives $12.5M USD in Funding

The Series A funding round, led by Investissement Quebec along with Desjardins Capital and Fondaction, was raised to expand commercialization activities in the United States and accelerate growth.

September 2023

1K Devices Milestone

The MY01 sets the gold standard for aiding in diagnosing compartment syndrome by surpassing a 1000 case milestone which highlights its vital role in enhancing clinical assessments.

We’re looking forward to all the exciting things to come!